MEDICAL ONCOLOGY

Abbrev. Title Protocol Title

1403-0008 Brightline-1

A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 compared to Doxorubicin as First Line Treatment of Patients with Advanced Dedifferentiated Liposarcoma

20190135 CodeBreak 101 A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination with Other Anti-cancer Therapies in Subjects with Advanced Solid Tumours with KRAS p.G12C Mutation (CodeBreak 101)

20-214-29 CA045-22

PIVOT-12

A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

213410 COSTAR Lung

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Nonsmall Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy

67652000PCR3002

AMPLITUDE

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

67652000PCR3002

AMPLITUDE

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

ABSK043-101

A Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumour

AD206-1001

A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects with Advanced/Metastatic Solid Tumors

ADG116-1003

A Phase 1b, Open-Label, Dose Escalation and Expansion Study of ADG116, ADG116 Combined with Toripalimab (Anti-PD-1 Antibody), ADG116 Combined with ADG106 (AntiCD137 Antibody) in Patients with Advanced/Metastatic Solid Tumours